fda compounding glp-1 enforcement news The is proposing the removal of three drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday FDA and Novo Nordisk Warned

Oral pentoxifylline associated with pentavalent antimony: a randomized trial for cutaneous leishmaniasis

Your choice should depend on your specific concerns, symptoms, and health profile

doi: 10.1093/sleep/26.3.337 26 SadehALaviePScherATiroshEEpsteinR

Ozempic lawsuits allege Novo Nordisk failed to adequately warn patients and healthcare providers about serious gastrointestinal risks including gastroparesis, pancreatitis, bowel obstruction, and vision loss (NAION)

Lilly is racing to file orforglipron for type 2 diabetes in 2026 while advancing retatrutide toward what could be the most efficacious obesity therapy yet studied